Stefan Verheye1, MD; Ricardo A. Costa2, MD; Joachim Schofer3, MD; John A. Ormiston4, MB, ChB; Michael Maeng5, MD; Dariusz Dudek6, MD; Carsten Skurk7, MD; Roberto V. Botelho8, MD; J. Ribamar Costa2, MD; Daniel Chamié2, MD; Andrea S. Abizaid9, MD; Eric Boersma10, PhD; Alexandre A. Abizaid2, MD
1. ZNA Middelheim, Antwerp, Belgium; 2. Instituto Dante Pazzanese, São Paulo, Brazil; 3. Universitäres Herz- und Gefäβzentrum Hamburg, Hamburg, Germany; 4. Mercy Hospital, Auckland, New Zealand; 5. Aarhus University Hospital, Aarhus, Denmark; 6. University Hospital in Krakow, Department of Interventional Cardiology, Krakow, Poland; 7. Charité - Universitätsmedizin Berlin, Campus Benjamin Franklin, Medizinische Klinik für Kardiologie, Berlin, Germany; 8. ICT/Instituto Do Coracao Do Triangulo Mineiro, Uberlandia, Brazil; 9. Cardiovascular Research Center, São Paulo, Brazil; 10. Erasmus MC, University Medical Center Rotterdam, Rotterdam, the Netherlands
Introduction
Bioresorbable scaffolds (BRS) were designed as an alternative to metallic stents with the goal of complete resorption to allow vascular remodelling and to decrease late clinical events associated with permanent implants1.
The DESolve® scaffold (Elixir Medical Corporation, Milpitas, CA, USA) is a next-generation scaffold with an early biodegradation and bioresorption profile that has demonstrated positive vascular remodelling at six months and favourable clinical outcomes2,3. The device is comprised of poly-L-lactic acid (PLLA) coated with a matrix of novolimus and a polylactide-based polymer. The strut thickness is 150 µm. We report the five-year clinical results with 18...
